|
Oct 7
|
Compugen to Present New Clinical Data at SITC 2024
|
|
Jul 30
|
Compugen receives FDA approval for Phase I trial of solid tumour treatment
|
|
Jul 29
|
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
|
|
Dec 21
|
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
|
|
Dec 20
|
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
|
|
Dec 20
|
Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
|
|
Dec 19
|
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
|
|
Dec 19
|
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
|
|
Dec 19
|
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
|
|
Dec 5
|
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
|
|
Nov 9
|
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
|
|
Nov 8
|
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Compugen Reports Third Quarter 2023 Results
|
|
Jul 17
|
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
|